Mt. Vernon man fights pancreatic cancer with innovative drug
Pancreatic cancer, which accounts for about 2 percent of new cancer diagnoses each year, is among the deadliest forms of the disease, but now there may be hope for some patients.
For Tom Martin, of Mount Vernon, it has been a long road from a Nov. 2009 diagnosis. Martin says his disease was caught in the early stages and doctors felt he was an ideal candidate for a clinical trial involving a new chemotherapy treatment that's getting incredible results.
Dr. Robert Fine, the medical oncology director at the Pancreas Center at NewYork-Presbyterian Hospital/Columbia University Medical Center, developed what's called the three-drug GTX regiment.
"When you give them together... they synergize multiple ways with each other, so they can kill drug resistant cells, which is very common in pancreatic cancer," Fine says.
In the past six months, Martin has gone through seven cycles of the GTX regiment, and underwent his eighth and final round today.
Doctors say Martin's recent tests indicate his cancer is in remission, but he will have to undergo tests every few months to ensure the cancer remains in remission.